These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Image Guided Hypofractionated Postprostatectomy Intensity Modulated Radiation Therapy for Prostate Cancer. Lewis SL; Patel P; Song H; Freedland SJ; Bynum S; Oh D; Palta M; Yoo D; Oleson J; Salama JK Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):605-11. PubMed ID: 26867889 [TBL] [Abstract][Full Text] [Related]
4. Long-term Tumor Control and Late Toxicity in Patients with Prostate Cancer Receiving Hypofractionated (2.2 Gy) Soft-tissue-matched Image-guided Intensity-modulated Radiotherapy. Shimizu D; Yamazaki H; Nishimura T; Aibe N; Okabe H Anticancer Res; 2017 Oct; 37(10):5829-5835. PubMed ID: 28982908 [TBL] [Abstract][Full Text] [Related]
5. Long-Term Outcomes of a Prospective Study on Highly Hypofractionated Intensity Modulated Radiation Therapy for Localized Prostate Cancer for 3 Weeks. Nakamura K; Ikeda I; Inokuchi H; Aizawa R; Ogata T; Akamatsu S; Kobayashi T; Mizowaki T Pract Radiat Oncol; 2023; 13(6):e530-e537. PubMed ID: 37414247 [TBL] [Abstract][Full Text] [Related]
6. Hypofractionated Dose Escalated 3D Conformal Radiotherapy for Prostate Cancer: Outcomes from a Mono-Institutional Phase II Study. Tramacere F; Arcangeli S; Pignatelli A; Castagna R; Portaluri M Anticancer Res; 2015 May; 35(5):3049-54. PubMed ID: 25964594 [TBL] [Abstract][Full Text] [Related]
7. Hypofractionated Radiation Therapy to the Prostate Bed With Intensity-Modulated Radiation Therapy (IMRT): A Phase 2 Trial. Leite ETT; Ramos CCA; Ribeiro VAB; Salvajoli BP; Nahas WC; Salvajoli JV; Ynoe Moraes F Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1263-1270. PubMed ID: 33346091 [TBL] [Abstract][Full Text] [Related]
8. Treatment outcome of high-dose image-guided intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer at a single institute in Japan. Takeda K; Takai Y; Narazaki K; Mitsuya M; Umezawa R; Kadoya N; Fujita Y; Sugawara T; Kubozono M; Shimizu E; Abe K; Shirata Y; Ishikawa Y; Yamamoto T; Kozumi M; Dobashi S; Matsushita H; Chida K; Ishidoya S; Arai Y; Jingu K; Yamada S Radiat Oncol; 2012 Jul; 7():105. PubMed ID: 22770471 [TBL] [Abstract][Full Text] [Related]
9. A Phase II trial of arc-based hypofractionated intensity-modulated radiotherapy in localized prostate cancer. Lock M; Best L; Wong E; Bauman G; D'Souza D; Venkatesan V; Sexton T; Ahmad B; Izawa J; Rodrigues G Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1306-15. PubMed ID: 20708855 [TBL] [Abstract][Full Text] [Related]
10. Long-term outcome of a moderately hypofractionated, intensity-modulated radiotherapy approach using an endorectal balloon for patients with localized prostate cancer. Teh BS; Lewis GD; Mai W; Pino R; Ishiyama H; Butler EB Cancer Commun (Lond); 2018 Apr; 38(1):11. PubMed ID: 29764515 [TBL] [Abstract][Full Text] [Related]
11. Impact of image guidance on toxicity and tumour outcome in moderately hypofractionated external-beam radiotherapy for prostate cancer. Jereczek-Fossa BA; Maucieri A; Marvaso G; Gandini S; Fodor C; Zerini D; Riva G; Alessandro O; Surgo A; Volpe S; Fanetti G; Arculeo S; Zerella MA; Parisi S; Maisonneuve P; Vavassori A; Cattani F; Cambria R; Garibaldi C; Starzyńska A; Musi G; De Cobelli O; Ferro M; Nolè F; Ciardo D; Orecchia R Med Oncol; 2018 Nov; 36(1):9. PubMed ID: 30483899 [TBL] [Abstract][Full Text] [Related]
12. Randomized Trial of Hypofractionated, Dose-Escalated, Intensity-Modulated Radiation Therapy (IMRT) Versus Conventionally Fractionated IMRT for Localized Prostate Cancer. Hoffman KE; Voong KR; Levy LB; Allen PK; Choi S; Schlembach PJ; Lee AK; McGuire SE; Nguyen Q; Pugh TJ; Frank SJ; Kudchadker RJ; Du W; Kuban DA J Clin Oncol; 2018 Oct; 36(29):2943-2949. PubMed ID: 30106637 [TBL] [Abstract][Full Text] [Related]
13. Hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer: late toxicity. Quon H; Cheung PC; Loblaw DA; Morton G; Pang G; Szumacher E; Danjoux C; Choo R; Thomas G; Kiss A; Mamedov A; Deabreu A Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):898-905. PubMed ID: 21237581 [TBL] [Abstract][Full Text] [Related]
14. Hypofractionated external beam radiotherapy to boost the prostate with ≥85 Gy/equivalent dose for patients with localised disease at high risk of lymph node involvement: feasibility, tolerance and outcome. Zilli T; Jorcano S; Escudé L; Linero D; Rouzaud M; Dubouloz A; Miralbell R Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):316-22. PubMed ID: 24667210 [TBL] [Abstract][Full Text] [Related]
15. Phase I trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancer. Adkison JB; McHaffie DR; Bentzen SM; Patel RR; Khuntia D; Petereit DG; Hong TS; Tomé W; Ritter MA Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):184-90. PubMed ID: 21163590 [TBL] [Abstract][Full Text] [Related]
16. Hypofractionated versus conventionally fractionated image-guided volumetric-modulated arc radiotherapy for localized prostate cancer: a phase II randomized trial from China. Zhong QZ; Xia X; Gao H; Xu YG; Zhao T; Wu QH; Wang D; Lin HL; Sha XY; Liu M; Li GF Aging (Albany NY); 2021 Feb; 13(5):6936-6944. PubMed ID: 33653964 [TBL] [Abstract][Full Text] [Related]
17. Hypofractionated Volumetric Modulated Arc Radiotherapy with simultaneous Elective Nodal Irradiation is feasible in prostate cancer patients: A single institution experience. Hegazy MW; Mahmood RI; Al Otaibi MF; Khalil EM J Egypt Natl Canc Inst; 2016 Jun; 28(2):101-10. PubMed ID: 27133975 [TBL] [Abstract][Full Text] [Related]
18. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Wilkins A; Mossop H; Syndikus I; Khoo V; Bloomfield D; Parker C; Logue J; Scrase C; Patterson H; Birtle A; Staffurth J; Malik Z; Panades M; Eswar C; Graham J; Russell M; Kirkbride P; O'Sullivan JM; Gao A; Cruickshank C; Griffin C; Dearnaley D; Hall E Lancet Oncol; 2015 Dec; 16(16):1605-16. PubMed ID: 26522334 [TBL] [Abstract][Full Text] [Related]
19. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial. Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287 [TBL] [Abstract][Full Text] [Related]
20. Toxicity assessment of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to prostate for intermediate- and high-risk prostate cancer. McCammon R; Rusthoven KE; Kavanagh B; Newell S; Newman F; Raben D Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):413-20. PubMed ID: 19362783 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]